Global Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Regional Outlook and Forecast, 2023 - 2030
The Global Androgenetic Alopecia Market size is expected to reach $4.6 billion by 2030, rising at a market growth of 8.1% CAGR during the forecast period.
Advancements in pharmaceutical R&D led to the discovery and development of innovative drugs for androgenetic alopecia. Therefore, the pharmaceuticals segment acquired $2,429.0 million revenue in 2022. New formulations and mechanisms of action expand the range of pharmaceutical options available to patients.
Cosmetic solutions are non-invasive and easy to use. Individuals can apply these products themselves, making them a convenient and user-friendly option for those who prefer non-surgical and non-pharmaceutical interventions. Thus, because of the increasing demand for cosmetic solutions, the market is anticipated to increase significantly.
Additionally, Androgenetic alopecia is more common in older age groups. The physiological changes associated with aging, such as hormonal shifts and reduced hair follicle function, contribute to a higher incidence of hair loss in the aging population. Hence, increasing number of senior citizens has been a pivotal factor in driving the growth of the market.
The market may experience disruptions in the supply chain, affecting the availability of pharmaceuticals, surgical instruments, and other related products. Delays in manufacturing and distribution can impact the delivery of treatments and interventions. Non-invasive and at-home solutions gained popularity. Thus, the COVID-19 pandemic had a moderate effect on the market.
However, High treatment costs may limit access to effective interventions, particularly for individuals with lower socioeconomic status or those without comprehensive health insurance coverage. This limited accessibility can result in a significant portion of the population being unable to afford advanced treatments. Thus, the high costs of some treatment options can slow down the growth of the market.
By Treatment Analysis
Based on treatment, the market is classified into pharmaceuticals and devices. The devices segment acquired a 3% revenue share in the market in 2022. The availability of devices for home use has expanded the reach of treatments. Home-use devices, such as laser caps and helmets, provide convenience for individuals seeking to address androgenetic alopecia in the comfort of their homes.
By Gender Analysis
By gender, the market is categorized into male and female. In 2022, the male segment acquired 70% revenue share in the market. Androgenetic alopecia is more prevalent in men than in women. As a result, men experiencing androgenetic alopecia may be more motivated to seek interventions to address hair loss, contributing to the uplift of the male segment in the market.
By Sales Channel Analysis
By sales channel, the market is segmented into prescriptions and OTC. The OTC segment recorded a remarkable 34% share in the market in 2022. The OTC segment offers a variety of products, including topical treatments, shampoos, supplements, and cosmetic solutions, providing consumers with diverse options to address their specific needs and preferences.
By End-use Analysis
On the basis of end-use, the market is divided into dermatology clinics and homecare settings. In 2022, the dermatology clinics segment dominated the market with 62.4% revenue share. These diagnostic tools help dermatologists accurately assess the severity and nature of androgenetic alopecia, guiding them in developing personalized treatment plans.
By Regional Analysis
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the 38.2% revenue share. In North America, individuals may start noticing hair loss in their 20s or 30s, increasing the risk.
List of Key Companies Profiled
- Cipla Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC (GSK)
- Sun Pharmaceuticals Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Aurobindo Pharma Limited
- Pfizer, Inc.
- Lutronic Co., Ltd.
- Viatris Inc.
- Eli Lilly and Company
By Treatment
- Pharmaceuticals
- Devices
- Male
- Female
- Prescriptions
- OTC
- Dermatology Clinics
- Homecare Settings
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Androgenetic Alopecia Market, by Treatment
- 1.4.2 Global Androgenetic Alopecia Market, by Gender
- 1.4.3 Global Androgenetic Alopecia Market, by Sales Channel
- 1.4.4 Global Androgenetic Alopecia Market, by End-use
- 1.4.5 Global Androgenetic Alopecia Market, by Geography
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Global Androgenetic Alopecia Market, By Treatment
- 4.1 Global Pharmaceuticals Market, By Region
- 4.2 Global Devices Market, By Region
- Chapter 5. Global Androgenetic Alopecia Market, By Gender
- 5.1 Global Male Market, By Region
- 5.2 Global Female Market, By Region
- Chapter 6. Global Androgenetic Alopecia Market, By Sales Channel
- 6.1 Global Prescriptions Market, By Region
- 6.2 Global OTC Market, By Region
- Chapter 7. Global Androgenetic Alopecia Market, By End-use
- 7.1 Global Dermatology Clinics Market, By Region
- 7.2 Global Homecare Settings Market, By Region
- Chapter 8. Global Androgenetic Alopecia Market, By Region
- 8.1 North America Androgenetic Alopecia Market
- 8.1.1 North America Androgenetic Alopecia Market, By Treatment
- 8.1.1.1 North America Pharmaceuticals Market, By Country
- 8.1.1.2 North America Devices Market, By Country
- 8.1.2 North America Androgenetic Alopecia Market, By Gender
- 8.1.2.1 North America Male Market, By Country
- 8.1.2.2 North America Female Market, By Country
- 8.1.3 North America Androgenetic Alopecia Market, By Sales Channel
- 8.1.3.1 North America Prescriptions Market, By Country
- 8.1.3.2 North America OTC Market, By Country
- 8.1.4 North America Androgenetic Alopecia Market, By End-use
- 8.1.4.1 North America Dermatology Clinics Market, By Country
- 8.1.4.2 North America Homecare Settings Market, By Country
- 8.1.5 North America Androgenetic Alopecia Market, By Country
- 8.1.5.1 US Androgenetic Alopecia Market
- 8.1.5.1.1 US Androgenetic Alopecia Market, By Treatment
- 8.1.5.1.2 US Androgenetic Alopecia Market, By Gender
- 8.1.5.1.3 US Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.1.4 US Androgenetic Alopecia Market, By End-use
- 8.1.5.2 Canada Androgenetic Alopecia Market
- 8.1.5.2.1 Canada Androgenetic Alopecia Market, By Treatment
- 8.1.5.2.2 Canada Androgenetic Alopecia Market, By Gender
- 8.1.5.2.3 Canada Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.2.4 Canada Androgenetic Alopecia Market, By End-use
- 8.1.5.3 Mexico Androgenetic Alopecia Market
- 8.1.5.3.1 Mexico Androgenetic Alopecia Market, By Treatment
- 8.1.5.3.2 Mexico Androgenetic Alopecia Market, By Gender
- 8.1.5.3.3 Mexico Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.3.4 Mexico Androgenetic Alopecia Market, By End-use
- 8.1.5.4 Rest of North America Androgenetic Alopecia Market
- 8.1.5.4.1 Rest of North America Androgenetic Alopecia Market, By Treatment
- 8.1.5.4.2 Rest of North America Androgenetic Alopecia Market, By Gender
- 8.1.5.4.3 Rest of North America Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.4.4 Rest of North America Androgenetic Alopecia Market, By End-use
- 8.2 Europe Androgenetic Alopecia Market
- 8.2.1 Europe Androgenetic Alopecia Market, By Treatment
- 8.2.1.1 Europe Pharmaceuticals Market, By Country
- 8.2.1.2 Europe Devices Market, By Country
- 8.2.2 Europe Androgenetic Alopecia Market, By Gender
- 8.2.2.1 Europe Male Market, By Country
- 8.2.2.2 Europe Female Market, By Country
- 8.2.3 Europe Androgenetic Alopecia Market, By Sales Channel
- 8.2.3.1 Europe Prescriptions Market, By Country
- 8.2.3.2 Europe OTC Market, By Country
- 8.2.4 Europe Androgenetic Alopecia Market, By End-use
- 8.2.4.1 Europe Dermatology Clinics Market, By Country
- 8.2.4.2 Europe Homecare Settings Market, By Country
- 8.2.5 Europe Androgenetic Alopecia Market, By Country
- 8.2.5.1 Germany Androgenetic Alopecia Market
- 8.2.5.1.1 Germany Androgenetic Alopecia Market, By Treatment
- 8.2.5.1.2 Germany Androgenetic Alopecia Market, By Gender
- 8.2.5.1.3 Germany Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.1.4 Germany Androgenetic Alopecia Market, By End-use
- 8.2.5.2 UK Androgenetic Alopecia Market
- 8.2.5.2.1 UK Androgenetic Alopecia Market, By Treatment
- 8.2.5.2.2 UK Androgenetic Alopecia Market, By Gender
- 8.2.5.2.3 UK Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.2.4 UK Androgenetic Alopecia Market, By End-use
- 8.2.5.3 France Androgenetic Alopecia Market
- 8.2.5.3.1 France Androgenetic Alopecia Market, By Treatment
- 8.2.5.3.2 France Androgenetic Alopecia Market, By Gender
- 8.2.5.3.3 France Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.3.4 France Androgenetic Alopecia Market, By End-use
- 8.2.5.4 Russia Androgenetic Alopecia Market
- 8.2.5.4.1 Russia Androgenetic Alopecia Market, By Treatment
- 8.2.5.4.2 Russia Androgenetic Alopecia Market, By Gender
- 8.2.5.4.3 Russia Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.4.4 Russia Androgenetic Alopecia Market, By End-use
- 8.2.5.5 Spain Androgenetic Alopecia Market
- 8.2.5.5.1 Spain Androgenetic Alopecia Market, By Treatment
- 8.2.5.5.2 Spain Androgenetic Alopecia Market, By Gender
- 8.2.5.5.3 Spain Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.5.4 Spain Androgenetic Alopecia Market, By End-use
- 8.2.5.6 Italy Androgenetic Alopecia Market
- 8.2.5.6.1 Italy Androgenetic Alopecia Market, By Treatment
- 8.2.5.6.2 Italy Androgenetic Alopecia Market, By Gender
- 8.2.5.6.3 Italy Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.6.4 Italy Androgenetic Alopecia Market, By End-use
- 8.2.5.7 Rest of Europe Androgenetic Alopecia Market
- 8.2.5.7.1 Rest of Europe Androgenetic Alopecia Market, By Treatment
- 8.2.5.7.2 Rest of Europe Androgenetic Alopecia Market, By Gender
- 8.2.5.7.3 Rest of Europe Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.7.4 Rest of Europe Androgenetic Alopecia Market, By End-use
- 8.3 Asia Pacific Androgenetic Alopecia Market
- 8.3.1 Asia Pacific Androgenetic Alopecia Market, By Treatment
- 8.3.1.1 Asia Pacific Pharmaceuticals Market, By Country
- 8.3.1.2 Asia Pacific Devices Market, By Country
- 8.3.2 Asia Pacific Androgenetic Alopecia Market, By Gender
- 8.3.2.1 Asia Pacific Male Market, By Country
- 8.3.2.2 Asia Pacific Female Market, By Country
- 8.3.3 Asia Pacific Androgenetic Alopecia Market, By Sales Channel
- 8.3.3.1 Asia Pacific Prescriptions Market, By Country
- 8.3.3.2 Asia Pacific OTC Market, By Country
- 8.3.4 Asia Pacific Androgenetic Alopecia Market, By End-use
- 8.3.4.1 Asia Pacific Dermatology Clinics Market, By Country
- 8.3.4.2 Asia Pacific Homecare Settings Market, By Country
- 8.3.5 Asia Pacific Androgenetic Alopecia Market, By Country
- 8.3.5.1 China Androgenetic Alopecia Market
- 8.3.5.1.1 China Androgenetic Alopecia Market, By Treatment
- 8.3.5.1.2 China Androgenetic Alopecia Market, By Gender
- 8.3.5.1.3 China Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.1.4 China Androgenetic Alopecia Market, By End-use
- 8.3.5.2 Japan Androgenetic Alopecia Market
- 8.3.5.2.1 Japan Androgenetic Alopecia Market, By Treatment
- 8.3.5.2.2 Japan Androgenetic Alopecia Market, By Gender
- 8.3.5.2.3 Japan Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.2.4 Japan Androgenetic Alopecia Market, By End-use
- 8.3.5.3 India Androgenetic Alopecia Market
- 8.3.5.3.1 India Androgenetic Alopecia Market, By Treatment
- 8.3.5.3.2 India Androgenetic Alopecia Market, By Gender
- 8.3.5.3.3 India Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.3.4 India Androgenetic Alopecia Market, By End-use
- 8.3.5.4 South Korea Androgenetic Alopecia Market
- 8.3.5.4.1 South Korea Androgenetic Alopecia Market, By Treatment
- 8.3.5.4.2 South Korea Androgenetic Alopecia Market, By Gender
- 8.3.5.4.3 South Korea Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.4.4 South Korea Androgenetic Alopecia Market, By End-use
- 8.3.5.5 Australia Androgenetic Alopecia Market
- 8.3.5.5.1 Australia Androgenetic Alopecia Market, By Treatment
- 8.3.5.5.2 Australia Androgenetic Alopecia Market, By Gender
- 8.3.5.5.3 Australia Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.5.4 Australia Androgenetic Alopecia Market, By End-use
- 8.3.5.6 Malaysia Androgenetic Alopecia Market
- 8.3.5.6.1 Malaysia Androgenetic Alopecia Market, By Treatment
- 8.3.5.6.2 Malaysia Androgenetic Alopecia Market, By Gender
- 8.3.5.6.3 Malaysia Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.6.4 Malaysia Androgenetic Alopecia Market, By End-use
- 8.3.5.7 Rest of Asia Pacific Androgenetic Alopecia Market
- 8.3.5.7.1 Rest of Asia Pacific Androgenetic Alopecia Market, By Treatment
- 8.3.5.7.2 Rest of Asia Pacific Androgenetic Alopecia Market, By Gender
- 8.3.5.7.3 Rest of Asia Pacific Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.7.4 Rest of Asia Pacific Androgenetic Alopecia Market, By End-use
- 8.4 LAMEA Androgenetic Alopecia Market
- 8.4.1 LAMEA Androgenetic Alopecia Market, By Treatment
- 8.4.1.1 LAMEA Pharmaceuticals Market, By Country
- 8.4.1.2 LAMEA Devices Market, By Country
- 8.4.2 LAMEA Androgenetic Alopecia Market, By Gender
- 8.4.2.1 LAMEA Male Market, By Country
- 8.4.2.2 LAMEA Female Market, By Country
- 8.4.3 LAMEA Androgenetic Alopecia Market, By Sales Channel
- 8.4.3.1 LAMEA Prescriptions Market, By Country
- 8.4.3.2 LAMEA OTC Market, By Country
- 8.4.4 LAMEA Androgenetic Alopecia Market, By End-use
- 8.4.4.1 LAMEA Dermatology Clinics Market, By Country
- 8.4.4.2 LAMEA Homecare Settings Market, By Country
- 8.4.5 LAMEA Androgenetic Alopecia Market, By Country
- 8.4.5.1 Brazil Androgenetic Alopecia Market
- 8.4.5.1.1 Brazil Androgenetic Alopecia Market, By Treatment
- 8.4.5.1.2 Brazil Androgenetic Alopecia Market, By Gender
- 8.4.5.1.3 Brazil Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.1.4 Brazil Androgenetic Alopecia Market, By End-use
- 8.4.5.2 Argentina Androgenetic Alopecia Market
- 8.4.5.2.1 Argentina Androgenetic Alopecia Market, By Treatment
- 8.4.5.2.2 Argentina Androgenetic Alopecia Market, By Gender
- 8.4.5.2.3 Argentina Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.2.4 Argentina Androgenetic Alopecia Market, By End-use
- 8.4.5.3 UAE Androgenetic Alopecia Market
- 8.4.5.3.1 UAE Androgenetic Alopecia Market, By Treatment
- 8.4.5.3.2 UAE Androgenetic Alopecia Market, By Gender
- 8.4.5.3.3 UAE Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.3.4 UAE Androgenetic Alopecia Market, By End-use
- 8.4.5.4 Saudi Arabia Androgenetic Alopecia Market
- 8.4.5.4.1 Saudi Arabia Androgenetic Alopecia Market, By Treatment
- 8.4.5.4.2 Saudi Arabia Androgenetic Alopecia Market, By Gender
- 8.4.5.4.3 Saudi Arabia Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.4.4 Saudi Arabia Androgenetic Alopecia Market, By End-use
- 8.4.5.5 South Africa Androgenetic Alopecia Market
- 8.4.5.5.1 South Africa Androgenetic Alopecia Market, By Treatment
- 8.4.5.5.2 South Africa Androgenetic Alopecia Market, By Gender
- 8.4.5.5.3 South Africa Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.5.4 South Africa Androgenetic Alopecia Market, By End-use
- 8.4.5.6 Nigeria Androgenetic Alopecia Market
- 8.4.5.6.1 Nigeria Androgenetic Alopecia Market, By Treatment
- 8.4.5.6.2 Nigeria Androgenetic Alopecia Market, By Gender
- 8.4.5.6.3 Nigeria Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.6.4 Nigeria Androgenetic Alopecia Market, By End-use
- 8.4.5.7 Rest of LAMEA Androgenetic Alopecia Market
- 8.4.5.7.1 Rest of LAMEA Androgenetic Alopecia Market, By Treatment
- 8.4.5.7.2 Rest of LAMEA Androgenetic Alopecia Market, By Gender
- 8.4.5.7.3 Rest of LAMEA Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.7.4 Rest of LAMEA Androgenetic Alopecia Market, By End-use
- Chapter 9. Company Profiles
- 9.1 Cipla Limited
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 SWOT Analysis
- 9.2 Merck & Co., Inc.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Segmental and Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
- 9.3 GlaxoSmithKline PLC (GSK)
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 SWOT Analysis
- 9.4 Sun Pharmaceuticals Industries Ltd.
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Regional Analysis
- 9.4.4 Research & Development Expenses
- 9.4.5 SWOT Analysis
- 9.5 Dr. Reddy’s Laboratories Ltd.
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Segmental and Regional Analysis
- 9.5.4 Research & Development Expense
- 9.5.5 Recent strategies and developments:
- 9.5.5.1 Product Launches and Product Expansions:
- 9.5.6 SWOT Analysis
- 9.6 Aurobindo Pharma Limited
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expense
- 9.6.5 SWOT Analysis
- 9.7 Pfizer, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Regional & Segmental Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
- 9.7.5.1 Trails and Approvals:
- 9.7.6 SWOT Analysis
- 9.8 Lutronic Co., Ltd.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Regional Analysis
- 9.8.4 Research & Development Expenses
- 9.8.5 SWOT Analysis
- 9.9 Viatris, Inc.
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Segmental Analysis
- 9.9.4 Research & Development Expense
- 9.9.5 SWOT Analysis
- 9.10. Eli Lilly And Company
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 SWOT Analysis
- Chapter 10. Winning Imperative of Androgenetic Alopecia Market
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook